Notes of 21nov2011 Alz. Assoc. CSF Reference Method Sub-group.

Slides:

Advertisements

Similar presentations

John Harrison, Michelle Garassi, Sara Wierzbicki, William LeBar Hospital Consolidated Laboratories-Providence Hospital, Southfield, MI, Evaluation of the.

Advertisements

1 Webinar: Assessment of the risk of human salmonellosis associated with the consumption of tree nuts Monday, July 22 nd 12 – 1 pm ET.

1 Global Biomarker Standardization Consortium Chairs: Holly Soares, Henrik Zetterberg, Piotr Lewczuk.

Office of Drug Evaluation IV, CDER FDA/IDSA/ISAP Workshop 4/16/04 Overview of PK-PD in Drug Development Programs: FDA Perspective FDA/IDSA/ISAP Workshop.

1 Thyroid Testing Strategies in the South-West and Wessex A survey conducted on behalf of the ACB SW&W Regional Committee by Roberta Goodall.

Research & Innovation Horizon societal challenge 1 Open Info Day Funding Opportunities for SMEs Horizon 2020 "Health, demographic change and wellbeing"

1 Global Biomarker Standardization Consortium: CSF Reference Method Sub-group Chairs: Kaj Blennow & Henrik Zetterberg.

1 Impurities: Positions of the regulatory authorities (like FDA and EMA) worldwide Dr. Christian Zeine, Warsaw, Nov 18, 2014 Science for a safer world.

The Practical Art of Endpoint Selection: Industry Perspectives A View from the Pharma Industry of the FDA Guidance on PROs Glenn A. Phillips, Ph.D. Director.

Bringing Metrology to Clinical Proteomic Research David Bunk Chemical Science and Technology Laboratory National Institute of Standards and Technology.

New Draft Guidance for Multiplex Tests Elizabeth Mansfield and Michele Schoonmaker Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD) CDRH/FDA.

Why publishing (and publishing in European Urology) is important for you Christian Gratzke Associate Editor European Urology How to Write a Manuscript.

Jeffrey Cossman, M.D. Standardizing the Evaluation of Diagnostics.

Proposal for End-of-Phase 2A (EOP2A) Meetings Advisory Committee for Pharmaceutical Sciences Clinical Pharmacology Subcommittee November 17-18, 2003 Lawrence.

Nos Commanditaires : IRIC 16 avril, h00 Salle S1-151 Pavillon Jean-Coutu Université de Montréal.

IB Computer Science – Logic

Validation Defination Establishing documentary evidence which provides a high degree of assurance that specification process will consistently produce.

BioPlex 2200 HIV Ag-Ab Assay

Introduction The composition of plasma and Cerebrospinal fluid (CSF) are similar with the only major difference between the two being the greatly reduced.

3M Drug Delivery Systems 3 Introduction A family of hydrofluoroalkane-compatible excipients based on oligomeric lactic acid (OLA) has been proposed for.

Introduction Feedback is ‘one of the most powerful ways to… enhance and strengthen student learning’ (Hepplestone et al 2009) Anecdotal evidence suggests.

Blood Based Biomarkers PIA

Alz. Assoc. CSF Reference Method Sub-group

Alz. Assoc. CSF Reference Method Sub-group

Patient Biospecimen Preanalytics:

CSF Round Robin Program

Meta-Analysis of a Possible Signal of Increased Mortality Associated with Cefepime Use Peter W. Kim, Yu-te Wu, Charles Cooper, George Rochester, Thamban.

Clinical Leadership Decision Process

Device Review Decision Tree Version Date: 4/28/15 This decision tree to be used for studies involving research on a device ( approved or unapproved)

Figure 2 The US Centers for Disease Control and

Fast Track Maintenance Process (for existing messages)

Median submission gap, median approval time and percentage approved as expedited for new active substances (NASs) approved by six authorities:

Current Therapy for Type II Diabetes

Identifying and validating biomarkers for Alzheimer's disease

Authors’ names to be inserted here, one or two lines in total

Comparison of median approval time of NASs by year of submission vs

Identifying and validating biomarkers for Alzheimer's disease

Management Philosophy

Standards Development for Metabolomics

Keng Wooi Ng PhD School of Pharmacy, Newcastle University @ngkengwooi

Authors’ names to be inserted here, one or two lines in total

From results to submission

Types of biomarkers/biosignatures to be used for cardiovascular disease. Types of biomarkers/biosignatures to be used for cardiovascular disease. There.

Conclusions/ Future Directions

Table 5. Sensory evaluation of mayonnaise samples

© The Author(s) Published by Science and Education Publishing.

Status of premarket submissions to FDA (data source: U. S

Premarket submissions to FDA (data source: U. S

© The Author(s) Published by Science and Education Publishing.

Comparison of median approval time of NASs by year of submission vs

EM Phases Conference Prague Oct 2018

© The Author(s) Published by Science and Education Publishing.

(A) Target 1 vs Target 2 - % of those diagnosed vs % of those diagnosed receiving ART. (B) Target 2 vs Target 3 - % of those diagnosed on ART vs % of those.

© The Author(s) Published by Science and Education Publishing.

Positivity rates and concordance of multiplex PCR and blood culture (BC) results from 27 published studies. Positivity rates and concordance of multiplex.

Table 1. Summary Statistics of Top Cut 1-m Samples

© The Author(s) Published by Science and Education Publishing.

Drug response profiles and experimental validation.

Financial Development

Global Cardiac Biomarkers Market

and Applications, 2016, Vol. 4, No. 2, doi: /jcsa-4-2-2

Table 2. SUMMARIZED OBSERVATIONS FROM MODEL ANALYSIS

Cumulative Percentage

Cumulative Percentage

95% Confidence Interval for Mean

Oil Absorption capacity(g/g)

Dependent Variable Statistic

Category Quantity Secondary school 3 Student participant

Presentation transcript:

Notes of 21nov2011 Alz. Assoc. CSF Reference Method Sub-group

Goal Quantify concentration of analyte as accurately as possible in the reference material to then be used to compare other methods and platforms available…

Methods to evaluate (for pros/cons) MRM published by Waters et al… (need cite) Absorbance based methods PPD (Randy Jenkins)- Assay from ICAD poster Proteome Sciences - “validated” ab42 assay C2N – quant ab42 and “total ab” assay Immunoassay based approaches – MSD, Myriad RBM, INNX/Fujirebio Manu Vandijeck had a new methodogy from Ab42 std working group… Note: need request validation reports from each.

Reference Methods Issues Issue: are we considering what is available today or what may need to get developed Consideration of pre-analytic methods and their impact on the analytical methods Oligomer vs monomer of Ab42 What is the minimum validation required? What is the quality standard? What is overall target goal? FDA clearance or approval, operate in research space only? Resources to achieve the goals? Suggest pull EMA opinions based on BMS submission regarding CSF biomarkers MSD-RUO initially, require more than MSD alone if tied to drug or indication, working on how take to next level, what are clinical study design and samples for a PMA... Invite DX companies: OCD, Roche to the “table”, CRO have done “validated” Pfizer/ICON, Issue: is method/assay validated and available? Where should it be done?